Close Menu

NEW YORK (GenomeWeb) – Enzo Biochem reported after the close of the market on Monday that its fourth quarter revenues fell 13 percent year over year, thanks mostly to a previously reported account loss, as well as to lower insurance reimbursement payments and shifts away from high-value genetic testing in the prior year.

For the three months ended July 31, the firm reported total revenues of $24.5 million, down from $28.2 million in Q4 2017.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The former commissioner of the FDA has returned to the venture capital firm New Enterprise Associates as a special partner on the healthcare investment team.

Astronauts have edited yeast genes on the International Space Station in an experiment designed to show how cells repair themselves in space.

Emory University has found that two of its researchers failed to divulge they had received funds from China, according to the Atlanta Journal-Constitution.

In Science this week: influence of the nuclear genome on human mitochondrial DNA, and more.